Patent application number | Description | Published |
20090299418 | CONCURRENT BILATERAL SPG MODULATION - Apparatus ( | 12-03-2009 |
20110230513 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSONS DISEASE - Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release | 09-22-2011 |
20120016434 | POST-ACUTE ELECTRICAL STIMULATION TREATMENT OF ADVERSE CEREBROVASCULAR EVENTS - A method for treatment is provided, including identifying that a subject has suffered from an adverse cerebrovascular event, excluding Alzheimer's disease and Parkinson's disease. Responsively to the identifying, beginning at least nine hours after the event, electrical stimulation is applied to a site of the subject selected from the group consisting of: a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve. The stimulation is configured to excite nervous tissue of the site at a strength sufficient to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow (CBF) of the subject, and a release of one or more neuroprotective substances. | 01-19-2012 |
20120301542 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF - The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof. | 11-29-2012 |
20130218249 | NEUROPROTECTIVE ELECTRICAL STIMULATION - Apparatus is provided that includes one or more electrodes, configured to be applied to a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, or a lesser deep petrosal nerve; and a control unit, configured to drive the electrodes to apply electrical stimulation to the site, and configure the stimulation to excite nervous tissue of the site at a strength sufficient to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow (CBF), and a release of one or more neuroprotective substances, and insufficient to induce a significant increase in permeability of a blood-brain barrier (BBB). | 08-22-2013 |